Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

Background: Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are poorly characterized in terms of molecular features and response to treatments. Methods: Patients with G3 GEP-NET were included if they received capecitabine and temozolomide (CAPTEM) or oxaliplatin with either 5-flu...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Giuseppe Lamberti, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim, Sara Pusceddu, Davide Campana
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2023-04-01
Schriftenreihe:	Diagnostics
Schlagworte:	NET G3 FOLFOX XELOX CAPTEM NGS
Online-Zugang:	https://www.mdpi.com/2075-4418/13/9/1595
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!